Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Angshu Bhowmik (Barnet, United Kingdom), Angshu Bhowmik, Arthur Tadique, Laura Graham, Matthew Hodson, Raj Rajakulasingam. Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team. Eur Respir J 2016; 48: Suppl. 60, 4058

Member's Comments

No comment yet.

Related content which might interest you: Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The influence of type of inhalation device on adherence of COPD patients to inhaled medication Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD Source: Annual Congress 2006 - COPD therapy Year: 2006 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 The adherence to inhaled drugs in COPD patients: Effect on survival Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Are COPD patients with chronic dyspnea and attending pulmonary rehabilitation treated with dual bronchodilatation or not? Source: International Congress 2016 – Best abstracts in COPD management Year: 2016 Differences in adherence to common inhaled medications in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Compare clinical effectiveness of various types of bronchodilators in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 The parameters that may affect inhalation therapy success in elderly COPD and asthma patients Source: International Congress 2015 – Co-existing diseases and asthma Year: 2015 Do inhaled corticosteroids reduce the frequent exacerbator phenotype in COPD - A little help by a multicenter survey Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 The clinical impact of long-acting bronchodilators in newly diagnosed COPD patients Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Comparison of protective effect of bronchodilators in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 The healthcare burden of non-compliance to pharmacotherapeutic escalation recommendations for COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Impacting patient-centred outcomes in COPD: exacerbations and hospitalisations Source: Eur Respir Rev 2006; 15: 47-51 Year: 2006